(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
In the early hours of July 1, 2013 Dutch biotech company Pharming Group NV (OTC:PHGUF) announced that the company has entered into a strategic collaboration with Shanghai Institute of Pharmaceutical Industry (SIPI), a Sinopharm Company (OTCPK:SHTDF), for the development, manufacture and commercialization of new products based on the Pharming technology platform. In addition, Pharming has also granted SIPI an exclusive license to commercialise Ruconest in China.
Ruconest for Heredity Angioedema (HAE) has been developed for the treatment of acute attacks of HAE. HAE is a rare genetic deficiency of C1 inhibitor activity resulting in recurrent attacks of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|